文献类型：期刊文献

中文题名：HBV DNA载量与HCC免疫治疗相互关系的研究进展

英文题名：Research progress on the relationship between HBV DNA load and immunotherapy for HCC

作者：马建国[1];夏任捷[1];杜晓宇[1];韩雄雄[2];马良斌[1];王勇[2];阎龙[1]

第一作者：马建国

机构：[1]解放军联勤保障部队第九四〇医院肝胆外科,兰州730050;[2]甘肃中医药大学第一临床医学院,兰州730030

第一机构：解放军联勤保障部队第九四〇医院肝胆外科,兰州730050

年份：2025

卷号：31

期号：10

起止页码：784

中文期刊名：中华肝胆外科杂志

外文期刊名：Chinese Journal of Hepatobiliary Surgery

收录：;北大核心:【北大核心2023】；

基金：甘肃省卫生健康行业科研基金(GSWSKY2021-043);兰州市科技计划(2024-9-131)。

语种：中文

中文关键词：乙型肝炎病毒;肝细胞癌;免疫治疗;免疫检查点抑制剂

外文关键词：Hepatitis B virus;Hepatocellular carcinoma;Immunotherapy;Immune checkpoint inhibitors

摘要：免疫疗法是肝细胞癌(HCC)的重要治疗方案,但其疗效受多种因素影响。乙型肝炎病毒(HBV)感染是诱发HCC的主要因素之一,HBV DNA复制可通过多种机制改变免疫微环境,上调程序性死亡受体1(PD-1)和程序性死亡配体1(PD-L1)表达,从而促进肿瘤的免疫逃逸。但PD-1/PD-L1的上调会增强PD-1/PD-L1抑制剂的应答率,增强抗肿瘤效应。本文旨在综述HBV DNA载量与PD-1/PD-L1抑制剂关系的研究进展,探讨其潜在的作用机制,为促进HBV相关HCC患者的个体化治疗提供科学依据。
Immunotherapy has become a pivotal treatment regimen for hepatocellular carcinoma(HCC);however,its efficacy is influenced by various factors.Hepatitis B virus(HBV)infection is one of the primary etiological factors leading to HCC.HBV DNA replication can alter the immune microenvironment through multiple mechanisms,notably by upregulating the expression of programmed cell death protein 1(PD-1)and its ligand(PD-L1),thereby facilitating tumor immune escape.Paradoxically,this upregulation of PD-1/PD-L1 may enhance the response rate to PD-1/PD-L1 inhibitors and potentiate the antitumor effect.This review aims to summarize current research progress on the relationship between HBV DNA load and the efficacy of PD-1/PD-L1 inhibitors,explore the underlying mechanisms,and provide a scientific basis for promoting personalized treatment strategies for patients with HBV-related HCC.